PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Some net income increase while AGEN is negative at -33.69%. John Neff would see a short-term edge over the struggling competitor.
8.54%
Some D&A expansion while AGEN is negative at -35.13%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Well above AGEN's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
48.65%
SBC growth while AGEN is negative at -23.97%. John Neff would see competitor possibly controlling share issuance more tightly.
-142.09%
Negative yoy working capital usage while AGEN is 139.43%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
Both negative yoy AP, with AGEN at -152.48%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-84.29%
Both reduce yoy usage, with AGEN at -98.41%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
47.93%
Some yoy increase while AGEN is negative at -125.05%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
1.55%
Operating cash flow growth below 50% of AGEN's 5.47%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut debt repayment yoy while AGEN is 4.08%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1131.77%
Stock issuance far above AGEN's 72.09%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.